Werewolf Therapeutics, Inc. (HOWL): Price and Financial Metrics
HOWL Price/Volume Stats
| Current price | $1.59 | 52-week high | $8.19 |
| Prev. close | $1.57 | 52-week low | $1.38 |
| Day low | $1.49 | Volume | 606,100 |
| Day high | $1.63 | Avg. volume | 382,294 |
| 50-day MA | $2.11 | Dividend yield | N/A |
| 200-day MA | $3.31 | Market Cap | 70.86M |
HOWL Stock Price Chart Interactive Chart >
Werewolf Therapeutics, Inc. (HOWL) Company Bio
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
HOWL Price Returns
| 1-mo | -10.67% |
| 3-mo | -27.40% |
| 6-mo | -39.08% |
| 1-year | -50.62% |
| 3-year | -86.47% |
| 5-year | N/A |
| YTD | -58.81% |
| 2023 | 88.29% |
| 2022 | -82.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...